melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 


theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery inflammation/arthritis

Contact Hypersensitivity
Contact hypersensitivity models mimic contact dermatitis aspects of immune function.  Many cutaneous disorders are characterized by inflammation.  The immune reaction induced by the method described below causes epidermal swelling at the site of challenge.  melior has established models of allergic contact hypersensitivity using oxazolone, DNFB and other haptens.  The localized inflammatory responses can be attenuated by corticosteroids and topical agents used to treat atopic dermatitis. 

        

Five days after baseline and initial sensitization to either oxazolone or DNFB, animals are administered compound and challenged with hapten. Any resulting sensitivity (i.e: swelling and/or redness) is mechanically measured and visually scored 24 hours after the challenge.

 

The figures illustrate the visual scoring (0 = no swelling or redness; 1 = minor swelling or redness; 2 = moderate swelling and some redness; 3 = severe swelling and prominent redness) and the tissue thickness after the challenge. Both agents produced an allergic reaction measured as tissue swelling and visual score.

 

Dexamethasone significantly attenuated the allergic reaction compared to vehicle-treated animals (***p<0.001). Data are mean ± SEM; ***p<0.001 compared to vehicle.

If you are interested in learning more about Contact Hyperesensitivity, please contact models@meliordiscovery.com to start the conversation.